Singapore markets closed

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4955-0.0104 (-2.06%)
At close: 04:00PM EDT
0.4950 -0.00 (-0.10%)
After hours: 05:54PM EDT
Full screen
Loading interactive chart…
  • Business Wire

    Exicure, Inc. Reports Third Quarter 2023 Financial Results

    CHICAGO, May 16, 2024--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.

  • Business Wire

    Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

    CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe

  • Business Wire

    Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

    CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.